Aristides Capital’s Relay Therapeutics RLAY Stock Holding History

Aristides Capital’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-43,400	Closed	-$179K	–	319
2024 Q4	$179K	Buy	+43,400	New	+$236K	0.04%	260

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Aristides Capital's RLAY Position: Q1 2025 in Review

Aristides Capital sold out of Relay Therapeutics (RLAY) in Q1 2025, closing a stake of 43,400 shares — an estimated $179K sold.

Aristides Capital first reported a position in RLAY in Q4 2024 and held it in 1 quarter. The position peaked at $179K in Q4 2024. 207 funds tracked by Wall St. Rank hold RLAY as of Q1 2025.

Aristides Capital reported no remaining Relay Therapeutics position as of Q1 2025 after selling out during the quarter.
Aristides Capital sold 43,400 Relay Therapeutics shares in Q1 2025, an estimated $179K.
Aristides Capital first reported a position in Relay Therapeutics in Q4 2024 and held it in 1 quarter.
Aristides Capital's Relay Therapeutics position peaked at $179K in Q4 2024.
207 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2025.

Based on Aristides Capital's 13F filing for Q1 2025, filed 14 May 2025.